News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Approves Eisai Company, Ltd. (ESALY.PK)'s Higher Aricept Dose for Alzheimer's Despite Warning


3/23/2012 8:01:48 AM

Four months before a best-selling Alzheimer’s drug was set to lose its patent protection, its makers received approval for a higher dosage that extended their exclusive right to sell the drug. But the higher dosage caused potentially dangerous side effects and worked only slightly better than the existing drugs, according to an article published Thursday in the British Medical Journal. The drug, Aricept 23, was approved in July 2010 against the advice of reviewers at the Food and Drug Administration.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES